Brilliant Violet 711™ anti-human CD8a Antibo
- 产品名称：
- Brilliant Violet 711™ anti-human CD8a Antibo
- 产品类别：
- 抗体
- 产品编号：
- 301043
- 产品应用：
- 301043
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 2884 |
1 |
- Verified Reactivity
- Human, Cynomolgus, Rhesus
- Reported Reactivity
- Chimpanzee, Baboon, Pigtailed Macaque, Sooty Mangabey
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
Brilliant Violet 711? excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).
- Application References
(PubMed link indicates BioLegend citation) -
- Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
- Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
- Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
- Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
- Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Rout N, et al. 2010. PLoS One 5:e9787. (FC)
- Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
- Product Citations
-
- Krebs SJ, et al. 2019. Immunity. 50:677. PubMed
- Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
- Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed
- Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed
- Mandolesi M, et al. 2021. Cell Reports Medicine. 2(4):100252. PubMed
- Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
- Demers K, et al. 2016. PLoS Pathog. 12: 1005805. PubMed
- Cartwright E, et al. 2014. J Immunol. 192:4666. PubMed
- Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
- Gurusamy D, et al. 2020. Cancer Cell. 37(6):818-833.e9. PubMed
- Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
- Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
- Medler TR et al. 2018. Cancer cell. 34(4):561-578 . PubMed
- Serwas NK, et al. 2019. Nat Commun. 2.573611111. PubMed
- Gao Y, et al. 2022. Immunity. 55:1732. PubMed
- Iwamoto N, et al. 2021. PLoS One. 16:e0248973. PubMed
- Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed
- Cale EM et al. 2017. Immunity. 46(5):777-791 . PubMed
- Om K, et al. 2020. PLoS Pathog. 16:e1008764. PubMed
- Singh KS, et al. 2021. Nature. 589:597. PubMed
- Misheva M, et al. 2022. Nat Commun. 13:139. PubMed
- Chowdhury A, et al. 2015. J Virol. 89: 8677-8686. PubMed
- RRID
- AB_11218793 (BioLegend Cat. No. 301043) AB_2562906 (BioLegend Cat. No. 301044)
- Structure
- Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
- Distribution
-
Majority of thymocytes, T cell subset, NK cells
- Function
- MHC class I co-receptor, thymic differentiation, T cell activation
- Ligand/Receptor
- MHC Class I molecules
- Cell Type
- Dendritic cells, NK cells, T cells, Thymocytes, Tregs
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.
- Gene ID
- 925 View all products for this Gene ID
- UniProt
- View information about CD8a on UniProt.org
